Targeting erk with novel inhibitor asn007
WebJun 16, 2024 · We developed a potent, selective ERK1/2 inhibitor, ASN007, with anti-tumor activity in both solid tumors and lymphoma models with BRAF and RAS mutations and also in a melanoma PDX model resistant to BRAF and MEK inhibitors. ASN007 synergizes with PI3K inhibitors both in vitro and in vivo. Our data show that the selective ERK1/2 inhibitor … WebJun 16, 2024 · We developed a potent, selective ERK1/2 inhibitor, ASN007, with anti-tumor activity in both solid tumors and lymphoma models with BRAF and RAS mutations and …
Targeting erk with novel inhibitor asn007
Did you know?
WebASN007 is an oral ERK1/2 inhibitor; an open-label, dose-escalation phase I study of ASN007 began in January 2024 and is still ongoing. However, to date, little is known about … WebFeb 5, 2024 · Asana BioSciences to Present Clinical Data on Oral ASN007, A Novel ERK1/2 Inhibitor, at the 32nd EORTC-NCI-AACR Symposium ... Once-Weekly, ASN007, a Novel ERK 1/2 Inhibitor, at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference ... (BRAF/PI3K inhibitor) and ASN007 (ERK1/2 inhibitor) at the American …
WebApr 10, 2024 · ASN007 is a potent inhibitor of the extracellular-signal-regulated kinases, ERK1 and ERK2 (ERK1/2), key players in the RAS/RAF/MEK (MAPK) signaling pathway. This pathway is frequently hyper ... WebASN007 (ASN-007) is a potent, selective, orally bioavailable ERK1/2 inhibitor with IC50 of 2 nM against both. ASN007 demonstrated a selective inhibition of ERK1/2 kinases at 1 uM in a panel of 335 serine/threonine, tyrosine, and protein lipid kinases. ASN007 shows strong antiproliferative activity in cancer cells harboring mutations in BRAF and ...
Web(A) PDAC cell lines were treated with vehicle control or variable concentrations of VS-5584 in 96-well plates for 48 h from publication: Targeting ERK enhances the cytotoxic effect of the novel ... WebWe do not sell to patients. Description: ASN007 (ASN-007) is a novel, potent, orally bioavailable and selective inhibitor of ERK1/2 with robust antitumor activity. It inhibits the RAS/RAF/MEK/ERK (MAPK) signaling pathway. ASN007 shows potent preclinical activity in KRAS-driven models, irrespective of subtype mutation, and in BRAF mutant models ...
National Center for Biotechnology Information
WebJan 1, 2024 · Therefore, targeting ERK would be an attractive strategy for the treatment of a variety of tumor types harboring acquired resistance to TKIs. Several ERK inhibitors … give me youtube to watchWebwith an MEK inhibitor to impede ERK activation. Furthermore, selective ERK inhibitors may be a promising strategy for minimizing toxicity and enhancing activity. ASN007 is an oral ERK1/2 inhibitor; an open-label, dose-escalation phase I study of ASN007 began in January 2024 and is still ongoing. However, to date, little is known about give microsoft points familyWebASN007. Catalog No.S9975 Synonyms: ERAS 007,ERK-IN-3. For research use only. ASN007 (ERAS 007, ERK-IN-3) is a potent and orally active inhibitor of ERK. ERK-IN-3 inhibits … further reachWebOct 24, 2024 · ASN007 is in Phase 1 clinical development. It is a potent inhibitor of the extracellular-signal-regulated kinases ERK1 and ERK2, which are key players in the … further rangeWebIncreased ERK activation was also found in in vitro models of acquired EGFR TKI resistance. ASN007 is a potent selective ERK1/2 inhibitor with promising antitumor activity in cancers with BRAF and RAS mutations. ASN007 treatment impeded tumor cell growth and the cell cycle in EGFR TKI-resistant cells. further rail strikesWebOct 22, 2024 · Title: Targeting ERK with novel inhibitor ASN007. Presenter: Filip Janku, MD, PhD. Associate Professor, Investigational Cancer Therapeutics (Phase I Clinical Trials … further rate hikesfurther rapper